Journal: Cells

Article Title: The Expression and Secretion Profile of TRAP5 Isoforms in Gaucher Disease

doi: 10.3390/cells13080716

Figure Lengend Snippet: Expression of ACP5, Chit1, and MCP-1 mRNA in macrophages. ( A ) Basal levels of ACP5, MCP1, and Chit1 in control (n = 9) vs. GD macrophages (n = 9) were measured by q-RT-PCR. Values are averages +/− SEM. t -test p < 0.005. ( B ) Macrophages derived from healthy control PBMCs were treated with healthy control plasma (n = 5), and plasma collected from GD patients with normal bone mineral density (NB, n = 3), osteopenia (OSN, n = 4), and osteoporosis (OSR, n = 2). ACP5 was measured by q-RT-PCR. Values are averages +/− SEM. ( C ) Macrophages derived from GD PBMC were treated with plasma collected from GD patients with normal bone mineral density (NB), osteopenia (OSN), and osteoporosis (OSR). ACP5 was measured by q-RT-PCR. Values are averages +/− SEM. ( D , E ) Macrophages derived from healthy control and GD PBMCs were treated with plasma collected from healthy controls (n = 4) and GD patients (n = 3). q-RT-PCR measured Chit1 ( D ) and MCP-1 ( E ). Values are averages +/− SEM. ( F ) Macrophages derived from GD PBMCs were treated with increasing concentrations of Lyso-Gb-1 for 1 and 24 h. ACP5 was measured by q-RT-PCR. Values are averages +/− SEM. ( G ) THP-1 cells were treated with the indicated concentrations of Lyso-Gb-1, or vehicle control, for 1, 2, 3, and 4 h, and q-RT-PCR of ACP5 was performed. * Statistically significant differences.

Article Snippet: Fresh PBMCs were isolated using SepMate TM PBMCs isolation tubes (Stemcells Technology, Cambridge, MA, USA), following the manufacturer’s protocol.

Techniques: Expressing, Control, Reverse Transcription Polymerase Chain Reaction, Derivative Assay, Clinical Proteomics